Immunovant Ownership | Who Owns Immunovant?
Immunovant Ownership Summary
Immunovant is owned by 56.30% institutional investors, 57.08% insiders. Fmr is the largest institutional shareholder, holding 8.94% of IMVT shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.94% of its assets in Immunovant shares.
IMVT Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Immunovant | 56.30% | 57.08% | -13.38% |
| Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
| Industry | Biotech Stocks | 307.00% | 11.11% | -218.12% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 13.10M | 8.94% | $324.44M |
| Deep track capital, lp | 9.50M | 5.56% | $152.00M |
| Vanguard group | 6.68M | 4.56% | $165.45M |
| T. rowe price investment management | 6.88M | 4.03% | $110.06M |
| Blackrock | 4.92M | 3.56% | $129.79M |
| Blackrock funding, inc. /de | 5.85M | 3.42% | $93.57M |
| Baker bros. advisors lp | 5.46M | 3.19% | $87.33M |
| Armistice capital | 5.20M | 3.04% | $83.20M |
| State street | 2.72M | 1.97% | $71.78M |
| Point72 asset management | 3.34M | 1.95% | $53.38M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Alpine global management | 2.63M | 9.47% | $42.03M |
| Stempoint capital lp | 1.30M | 6.68% | $20.81M |
| Deep track capital, lp | 9.50M | 4.87% | $152.00M |
| Great point partners | 262.18K | 2.73% | $4.19M |
| Prosight management, lp | 479.40K | 1.87% | $7.67M |
| Armistice capital | 5.20M | 1.44% | $83.20M |
| Adar1 capital management | 535.07K | 1.31% | $8.56M |
| Perceptive advisors | 2.14M | 1.27% | $34.21M |
| Boxer capital | 825.00K | 1.15% | $21.78M |
| Highvista strategies | 182.81K | 1.07% | $2.92M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Point72 asset management | 3.34M | 0.10% | 2.53M |
| T. rowe price investment management | 6.88M | 0.07% | 984.13K |
| Jpmorgan chase | 1.15M | 0.00% | 925.08K |
| Armistice capital | 5.20M | 1.44% | 700.00K |
| Norges bank | 637.95K | 0.00% | 637.95K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | - | - | -1.36M |
| Hood river capital management | 100.00 | - | -1.18M |
| Viking global investors lp | - | - | -1.11M |
| Franklin resources | - | - | -984.06K |
| Capital research global investors | - | - | -976.24K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Norges bank | 637.95K | 0.00% | 637.95K | $15.80M |
| Balyasny asset management | 197.57K | 0.00% | 197.57K | $3.16M |
| Bnp paribas arbitrage, snc | 85.20K | 0.00% | 85.20K | $2.11M |
| J. goldman & co lp | 34.34K | 0.02% | 34.34K | $850.53K |
| Lmr partners llp | 25.07K | 0.00% | 25.07K | $401.07K |
Sold Out
| Holder | Change |
|---|---|
| Reuter james wealth management | -1.00 |
| Physician wealth advisors | -1.00 |
| Capital performance advisors llp | -3.00 |
| Nelson, van denburg & campbell wealth management group | -11.00 |
| Cibc private wealth group | -17.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 178 | -15.64% | 96,201,301 | 3.59% | 56 | 1.41% | 96 | -25.58% | 50 | 19.05% |
| Mar 31, 2025 | 212 | 2.42% | 94,119,777 | 17.45% | 64 | 2.15% | 130 | 23.81% | 43 | -30.65% |
| Dec 31, 2024 | 197 | -3.90% | 76,056,919 | -3.29% | 51 | 1.80% | 100 | 5.26% | 58 | -9.38% |
| Sep 30, 2024 | 204 | -4.23% | 78,645,357 | 5.27% | 53 | 2.05% | 94 | -14.55% | 64 | - |
| Jun 30, 2024 | 211 | -10.21% | 74,707,025 | 7.20% | 54 | 2.33% | 109 | 0.93% | 63 | -23.17% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 6.74M | 3.94% | 196.05K |
| Fidelity Growth Compy Commingled Pl O | 4.45M | 3.04% | 196.00K |
| Fidelity Growth Company Fund | 4.84M | 2.83% | 150.10K |
| T. Rowe Price Small-Cap Stock | 2.55M | 1.49% | -2.98K |
| T. Rowe Price US Small-Cap Core Equity | 2.55M | 1.49% | 140.80K |
| Vanguard US Total Market Shares ETF | 2.12M | 1.25% | 2.26K |
| Vanguard Total Stock Mkt Idx Inv | 2.13M | 1.24% | -47.17K |
| Vanguard Small Cap Index | 1.66M | 0.97% | -11.12K |
| iShares Russell 2000 ETF | 1.60M | 0.93% | -30.34K |
| Fidelity Growth Company K6 | 1.47M | 0.86% | 57.75K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | $50.91K |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | $43.29K |
| Jul 09, 2025 | Geffner Michael | Chief Medical Officer | Sell | $20.00K |
| Jul 09, 2025 | Stout Jay S | Chief Technology Officer | Sell | $26.19K |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | $28.47K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 4 |
| 2025 Q2 | - | 5 |
| 2025 Q1 | 1 | 17 |
| 2024 Q4 | - | 16 |
| 2024 Q3 | - | 28 |
IMVT Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools